EUVIMEDEUVIMED entdecken
Crossref

[ 68 Ga]Ga-DOTA-CEND1: A Novel PET Cyclic Peptide Tracer for Noninvasive Imaging of Neuropilin-1 Expression in Pan-Tumors

Fengshuang Qiu, Shuang Tang, Xuwei Liu, Jialiang Lei, Linjie Bian, Fengsheng Zhang, Xiaoyu Pan, Xiaoping Xu, Simin He, Jianping Zhang, Jindian Li iD, Shaoli Song iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Fengshuang Qiu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center Shanghai 200032, China. Hauptthemen laut MEDLINE: Neuropilin-1, Peptides, Cyclic, Gallium Radioisotopes, Radiopharmaceuticals. Die Arbeit nennt 35 Literaturangaben. Gefördert von: State Key Laboratory of Oral Disease, Science and Technology Commission of Shanghai Municipality, Science and Technology Commission of Fengxian District, Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a transmembrane glycoprotein overexpressed in various tumors, neuropilin-1 (NRP-1) is involved in tumor progression, angiogenesis, and immune evasion. This study developed a novel PET cyclic peptide radiotracer [68Ga]Ga-DOTA-CEND1 for NRP-1 detection specifically and sensitively across multiple tumor types, potentially guiding personalized NRP-1 therapeutic regimens. NRP-1 expression was assessed and confirmed through immunohistochemical analysis of tissue microarrays, Western blot, immunohistochemistry, and immunofluorescence staining. The biochemical properties of the probe were investigated through radiochemical purity, lipid-water partition coefficient, pharmacokinetics, in vivo and in vitro stabilities, and biosafety studies. To determine diagnostic sensitivity and clinical applicability, cellular uptake assays, micro positron-emission tomography/computed tomography (PET/CT), blocking studies, and ex vivo biodistribution were performed in four NRP-1 positive tumor models (fibrosarcoma, TNBC, NSCLC, and pancreatic tumor) and one NRP-1-negative model (cervical tumor). [68Ga]Ga-DOTA-CEND1 demonstrated >95% radiochemical purity, optimal pharmacokinetics, favorable hydrophilicity, robust in vivo and in vitro stability, and an ideal biosafety profile. Micro PET/CT at 1 h postinjection revealed significantly higher tumor uptake in NRP-1 positive tumor models than in the NRP-1 negative tumor model, while coinjection with nonradioactive CEND-1 significantly reduced tumor uptake, and tumor-to-muscle ratios aligned with NRP-1 expression levels, confirming the specificity and sensitivity of the radiotracer. As the first PET cyclic peptide radiotracer, [68Ga]Ga-DOTA-CEND1 holds great potential for noninvasively detecting NRP-1 expression across tumor types, optimizing NRP-1 targeted therapy, and evaluating therapeutic responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuropilin-1Peptides, CyclicGallium RadioisotopesRadiopharmaceuticalsNeoplasmsAnimalsHumansMicePositron Emission Tomography Computed TomographyTissue DistributionCell Line, TumorFemaleHeterocyclic Compounds, 1-RingPositron-Emission TomographyMice, NudeMice, Inbred BALB C

Stichwörter der Autor:innen

CEND-1PET/CT imagingneuropilin-1(NRP-1)precision medicinetumour diagnosis

Substanzen

Neuropilin-1Peptides, CyclicGallium RadioisotopesRadiopharmaceuticalsHeterocyclic Compounds, 1-RingGallium-68

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center Shanghai 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.
  • Center for Biomedical Imaging, Fudan UniversityShanghai 200032, China.
  • Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai 200032, China.
  • Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai 200433, China.
  • College of Chemistry and Materials Science, Shanghai Normal University, Shanghai 200233, China.

ORCID-Profile: Jindian Li, Shaoli Song

Förderung

  • State Key Laboratory of Oral Disease
  • Science and Technology Commission of Shanghai Municipality
  • Science and Technology Commission of Fengxian District, Shanghai Municipality
  • National Natural Science Foundation of China
  • National Isotope Engineering Technology Research Center
  • State Key Laboratory of Complex, Severe, and Rare Diseases

Zitieren

APA

Qiu, F., Tang, S., Liu, X., Lei, J., Bian, L., Zhang, F., Pan, X., Xu, X., He, S., Zhang, J., Li, J., & Song, S. (2026). [ 68 Ga]Ga-DOTA-CEND1: A Novel PET Cyclic Peptide Tracer for Noninvasive Imaging of Neuropilin-1 Expression in Pan-Tumors. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01160

Vancouver

Qiu F, Tang S, Liu X, Lei J, Bian L, Zhang F, et al. [ 68 Ga]Ga-DOTA-CEND1: A Novel PET Cyclic Peptide Tracer for Noninvasive Imaging of Neuropilin-1 Expression in Pan-Tumors. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01160

BibTeX
@article{Qiu2026,
  author = {Qiu, Fengshuang and Tang, Shuang and Liu, Xuwei and Lei, Jialiang and Bian, Linjie and Zhang, Fengsheng and Pan, Xiaoyu and Xu, Xiaoping and He, Simin and Zhang, Jianping and Li, Jindian and Song, Shaoli},
  title = {[ 68 Ga]Ga-DOTA-CEND1: A Novel PET Cyclic Peptide Tracer for Noninvasive Imaging of Neuropilin-1 Expression in Pan-Tumors},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01160}
}
Kostenlos starten →